Alset receives Nasdaq notice for non-compliance with minimum bid price rule

Alset received a Nasdaq deficiency notice after its shares closed below the $1.00 minimum bid price for 30 consecutive trading days; the stock was at $0.51, down roughly 82% over the past year and 85% year-to-date. The company has until April 26, 2027, to meet the requirement by closing at or above $1.00 for 10 consecutive business days, and says the notice does not immediately affect its listing. Alset has previously announced plans for a 1-for-5 reverse split; failure to regain compliance or qualify for extra time could lead to delisting proceedings.

Analysis

This is a market-structure and financing-access risk, not a fundamental valuation signal. A reverse split can lift the quoted price above Nasdaq’s threshold mechanically, but it does not improve enterprise value, operating performance, or the ability to sustain a bid; post-split liquidity and renewed selling are the key risks. The compliance window creates a near-term event calendar, while an additional cure period or appeal could defer—not remove—the listing overhang. Any forced selling or reduced willingness by counterparties to engage with a distressed microcap could amplify volatility, although the article provides no evidence on Alset’s financing needs or shareholder composition.

The contrarian case is that the severe decline may already discount substantial distress, but the cited “undervaluation” claim is not independently substantiated here. A low share price and oversold conditions are not catalysts. Over the next 1–3 months, the split’s timing, post-split trading, and bid-price persistence matter more than the nominal reset; over 6–18 months, operating results and capital access determine whether compliance translates into durable value. Falsifiers: a sustained post-split bid above $1 and improving reported fundamentals would weaken the distress thesis; continued price weakness, failure to meet other listing standards, or a delisting notice would strengthen it.

Key Decisions for Investors

• Do not treat the proposed 1-for-5 reverse split as value creation or buy solely on the mechanically higher share price. Verify the effective date, final split ratio, and post-split share count before reassessing.
• No compelling directional trade without verified borrow availability, liquidity, and balance-sheet data. A short can face sharp squeeze risk around the split or a compliance announcement; avoid expressing the view through an illiquid position.
• For existing exposure, avoid averaging down ahead of the corporate-action and listing catalysts; size for potential gaps and reassess after post-split trading and the next financial disclosures.
• Watch for a sustained bid-price recovery, eligibility for an additional compliance period, and any Nasdaq delisting determination or appeal. A split followed by renewed weakness, or deteriorating reported fundamentals, would invalidate a recovery thesis.